IL-APTARGROUP
26.5.2021 14:32:09 CEST | Business Wire | Press release
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announces the launch of the company’s first fully recyclable mono-material pump for the beauty and personal care industries, called Future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210526005198/en/
Certified and Sustainable by Design
In order to facilitate recycling, Future was designed using polyethylene (PE) mono-material only. Future is certified by Cyclos-HTP, the institute for Recyclability and Product Responsibility * . The innovation is also recognized “A” by RecyClass – a comprehensive cross-industry initiative that works to establish a harmonized recycling approach and traceability in Europe*.
“Today we are pleased to launch our latest sustainable innovation, Future, a game changing dispensing solution. Following more than two years of design, engineering and testing, I am very proud of our team’s mono-material design and it truly reflects our commitment to a more circular economy,” said Marc Prieur, President, Aptar Beauty + Home.
In developing the concept for Future, Aptar’s experts turned to recognized eco-design principles, which call for plastic dispensing products to be made from a mono-material to facilitate the recycling process. Traditional pumps may contain different materials, including metal components that can in some cases complicate the recycling process. Because the Future pump is made from PE only, it also aligns with the most common materials used to make bottles – PE and PET. Therefore, the complete packaging, including pump and bottle, are more easily recycled*.
Christophe Marie, Product Sustainability Director, Aptar, explains, “The ideal situation for the complete value chain is to have mono-material packaging where the container, the closure or dispensing system is made from the same material family. This was the big challenge our innovation team overcame with the development of Future.”
*Subject to local recyclability facilities and fully recyclable with PET and PE bottles.
RecyClass recognition applies for an undecorated clear or white pump.
Future is also available using post-consumer resin (PCR). Aptar Beauty + Home proudly obtained an International Sustainability & Carbon Certification (ISCC) for its European production.
“Our ultimate goal was to have the final consumer be able to take their body lotion, shampoo or shower gel and easily put the empty packaging in their recycling bin. This way, it enters a circular life cycle and can be turned into another product,” explained Sabine Bouillet-Lubot, Global Strategic Marketing Director, Aptar Beauty + Home.
E-Commerce Capable & Eco-Design
The Future pump combines the best eco-design principles with cutting-edge innovation. A stand-out feature of the Future pump’s innovative design is an incorporated on/off locking system and a 360° degree actuator. This modern take on closure design also renders Future compliant with the rigorous ISTA 6-Amazon protocol**. Designed for e-commerce, Future’s ISTA 6 compliance ensures that the pump withstands the risks associated with transport and distribution network pressures as well as necessitates less protective carton and paper packaging.
**Subject to final tests conducted by a brand’s bottle choice.
Sustainability at Aptar
Aptar believes that the packaging industry must move beyond the make, use, dispose behaviors of the past and actively work toward a circular economy. By circulating used plastic and packaging, we keep it in the economy and out of the environment. Therefore, reducing the quantity of plastic needed, using recycled materials and developing reuse models. Our vision is to design products and processes with people and the planet in mind and we are focusing our activities on three mains areas for sustainability: recycled materials, recyclability and reusability. Collaboration is essential to achieving a more circular economy, so we work with partners, suppliers and customers who share our vision. As a member of the Ellen MacArthur Foundation’s New Plastics Economy Global Commitment, this innovation highlights our pledge to reduce environmental impact and support the Foundation’s vision for a circular economy. We are working hard towards our 2025 goal to have all of our packaging 100% reusable, recyclable or compostable for our dispensing solutions for the beauty, personal care, home care and food and beverage markets.
Aptar to Present at the ChangeNow 2021 Global Summit
Aptar’s innovative dispensing solution will be introduced live at the ChangeNOW 2021 Global Summit on May 27th. As a proud supporting partner of ChangeNOW, Aptar’s Vice President of Global Sustainability, Beth Holland, will be a featured guest speaker during the circular economy panel discussion.
About Aptar
Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com .
This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005198/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
